Oruka Therapeutics (NASDAQ:ORKA) Shares Gap Down – Should You Sell?

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $93.29, but opened at $90.84. Oruka Therapeutics shares last traded at $85.7160, with a volume of 632,865 shares.

Analysts Set New Price Targets

A number of brokerages recently commented on ORKA. Wedbush set a $165.00 price objective on shares of Oruka Therapeutics in a research report on Monday, April 27th. Guggenheim set a $200.00 price objective on Oruka Therapeutics and gave the company a “buy” rating in a report on Monday, April 27th. Stifel Nicolaus boosted their target price on Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. BTIG Research reissued a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a research note on Thursday, May 14th. Finally, Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $134.30.

Oruka Therapeutics Stock Performance

The stock’s 50 day moving average price is $69.11 and its two-hundred day moving average price is $49.41. The firm has a market capitalization of $5.14 billion, a price-to-earnings ratio of -43.92 and a beta of -0.35.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.04. On average, sell-side analysts forecast that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current fiscal year.

Insider Activity at Oruka Therapeutics

In other news, SVP Arjun Agarwal sold 10,290 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $59.07, for a total transaction of $607,830.30. Following the sale, the senior vice president owned 16,406 shares of the company’s stock, valued at $969,102.42. The trade was a 38.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Carl Dambkowski sold 105,000 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $58.97, for a total value of $6,191,850.00. Following the completion of the sale, the director owned 73,743 shares in the company, valued at approximately $4,348,624.71. This represents a 58.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 185,407 shares of company stock valued at $11,636,307. 23.49% of the stock is currently owned by corporate insiders.

Institutional Trading of Oruka Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Legal & General Group Plc acquired a new stake in Oruka Therapeutics in the second quarter valued at $28,000. BNP Paribas Financial Markets raised its stake in shares of Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after buying an additional 2,306 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Oruka Therapeutics in the 4th quarter worth about $37,000. Finally, PNC Financial Services Group Inc. acquired a new stake in Oruka Therapeutics in the 3rd quarter valued at about $39,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.